For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Abide Therapeutics, Inc.

USPTO Granted Patents = 18

% Expired Patents = 11.1

CIPO Patents = 2

Forward Citations = 146

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Cheryl A Grice (17 out of 74 patents)

Justin S Cisar (12 out of 22 patents)

Todd Kevin Jones (12 out of 110 patents)

4. Olivia Delene Weber (9 out of 22 patents)

5. Micah J Niphakis (6 out of 11 patents)

6. Benjamin F Cravatt (5 out of 31 patents)

7. Jae Won Chang (4 out of 16 patents)

8. Katharine K Duncan (4 out of 11 patents)

9. Dong-Hui Wang (4 out of 4 patents)

10. Daniel J Buzard (3 out of 41 patents)

11. John J M Wiener (3 out of 28 patents)

12. Kenneth M Lum (3 out of 11 patents)

13. Nicole Suzanne White (2 out of 9 patents)

14. Michael B Shaghafi (2 out of 15 patents)

15. Yu Feng (2 out of 6 patents)

18 patents: Sort by Forward Citations

1. 11129827 - Dual MAGL and FAAH inhibitors (2021-09-28),

2. 11053199 - Crystalline (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof (2021-07-06),

3. 10350205 - Dual MAGL and FAAH inhibitors (2019-07-16),

4. 10336709 - Lp-PLA2 inhibitors (2019-07-02),

5. 10323038 - Pyrazole compounds and methods of making and using same (2019-06-18),

6. 10266497 - Pyrazole MAGL inhibitors (2019-04-23),

7. 10093635 - MAGL inhibitors (2018-10-09),

8. 10093630 - Pyrazole compounds and methods of making and using same (2018-10-09),

9. 10030020 - Spirocycle compounds and methods of making and using same (2018-07-24),

10. 9994537 - Piperazine carbamates and methods of making and using same (2018-06-12),

11. 9981972 - N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets (2018-05-29),

12. 9981930 - MAGL inhibitors (2018-05-29),

13. 9957242 - Carbamate compounds and methods of making and using same (2018-05-01),

14. 9828379 - Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof (2017-11-28),

15. 9771341 - Piperazine carbamates and methods of making and using same (2017-09-26),

Abide Therapeutics is a biopharmaceutical company that develops innovative therapeutics for neurological disorders. They specialize in targeting and modulating serine hydrolases, enzymes that play crucial roles in regulating the endocannabinoid system. Abide Therapeutics aims to create novel treatments for conditions such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Their mission is to improve the quality of life for patients by discovering groundbreaking therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

18 Patents

#328 in San Diego, CA

#4,278 in California

#17,933 in US

#34,146 in the World

San Diego, CA, United States of America

Abide Therapeutics, Inc.

Forward Citations = 146

26 inventors:

Cheryl A Grice (17 out of 74 patents)

Justin S Cisar (12 out of 22 patents)

Todd Kevin Jones (12 out of 110 patents)

4. Olivia Delene Weber (9 out of 22 patents)

5. Micah J Niphakis (6 out of 11 patents)

Please report any incorrect information to [email protected]

Loading…